LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

Search

Guardant Health Inc

Închisă

SectorSănătate

103.29 -2.37

Rezumat

Modificarea prețului

24h

Curent

Minim

99.21

Maxim

103.59

Indicatori cheie

By Trading Economics

Venit

7.2M

-93M

Vânzări

33M

265M

Marjă de profit

-34.965

Angajați

1,999

EBITDA

6.6M

-82M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+28.24% upside

Dividende

By Dow Jones

Următoarele câștiguri

29 apr. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

4.6B

14B

Deschiderea anterioară

105.66

Închiderea anterioară

103.29

Sentimentul știrilor

By Acuity

50%

50%

141 / 351 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

Guardant Health Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

22 feb. 2026, 23:55 UTC

Market Talk

Gold and Silver Rise Amid Renewed Trade Tensions -- Market Talk

22 feb. 2026, 23:53 UTC

Market Talk

Japan Activity Data Set to Show Strength, Backed by Fiscal Spending -- Market Talk

22 feb. 2026, 23:53 UTC

Market Talk

Key China Rates Likely to Be Held Steady for Now -- Market Talk

22 feb. 2026, 23:51 UTC

Market Talk

Bank of Korea Set to Hold Fire as Inflation Steadies, Risks Linger -- Market Talk

22 feb. 2026, 23:35 UTC

Market Talk

Oil Falls Amid Prospect That U.S. Strike on Iran Might Be Limited -- Market Talk

22 feb. 2026, 23:21 UTC

Câștiguri

Nickel Industries 2025 Adjusted Ebitda US$283.0 Million

22 feb. 2026, 23:20 UTC

Câștiguri

Nickel Industries 2025 Operating Profit US$126.4 Million

22 feb. 2026, 23:19 UTC

Câștiguri

Nickel Industries 2025 Revenue US$1.65 Billion, Down 5.5% On-Year

22 feb. 2026, 23:19 UTC

Câștiguri

Correct: Nickel Industries 2025 Net Loss US$57.1 Million, Down 66% On-Year

22 feb. 2026, 23:18 UTC

Câștiguri

Nickel Industries Won't Pay a Final Dividend

22 feb. 2026, 23:16 UTC

Câștiguri

Nickel Industries 2025 Net Loss A$57.1 Million, Down 66% On-Year

22 feb. 2026, 21:35 UTC

Câștiguri

Ampol Expects to Start Commissioning of Ultra Low Sulfur Fuels Project in 2Q

22 feb. 2026, 21:34 UTC

Câștiguri

Ampol Says F&I Australia, International Have Begun 2026 Strongly

22 feb. 2026, 21:34 UTC

Câștiguri

Ampol Expects Stage 1 of Fuel Security Services Payment Review Finalized in 1Q

22 feb. 2026, 21:33 UTC

Câștiguri

Ampol Says Lytton Refiner Margin Was US$8.13/bbl in January

22 feb. 2026, 21:33 UTC

Câștiguri

Ampol Recognizes A$89.9 Million Impairment in Carrying Value of Investment in Seaoil

22 feb. 2026, 21:28 UTC

Câștiguri

Ampol Final Dividend A$0.60/Share

22 feb. 2026, 21:28 UTC

Câștiguri

Ampol FY Revenue A$31.37 Billion, Down 10%

22 feb. 2026, 21:28 UTC

Câștiguri

Ampol FY Replacement-Cost Net Profit A$429.2 Million, Up 83%

22 feb. 2026, 21:28 UTC

Câștiguri

Ampol FY Historical-Cost Net Profit A$82.4 Million, Down 33%

21 feb. 2026, 14:31 UTC

Achiziții, Fuziuni, Preluări

Bridgewater Associates' 4Q Buying and Selling -- Barrons.com

21 feb. 2026, 05:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

20 feb. 2026, 23:12 UTC

Achiziții, Fuziuni, Preluări

FERC Authorizes TXNM Energy Acquisition by Blackstone Infrastructure

20 feb. 2026, 22:12 UTC

Câștiguri

Equinox Gold: Announces Filing of 2025 Audited Fincl Statements

20 feb. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

20 feb. 2026, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

20 feb. 2026, 21:23 UTC

Câștiguri

These Stocks Are Today's Movers: Grail, Corning, Comfort Systems USA, Opendoor, Akamai, Chemours, and More -- Barrons.com

20 feb. 2026, 21:20 UTC

Market Talk

Century Aluminum Backs Trump's Tariffs After SCOTUS Ruling -- Market Talk

20 feb. 2026, 21:01 UTC

Achiziții, Fuziuni, Preluări

Want to Win the Warner Bros. Discovery Takeover Battle? 'Walk Away Now.' -- Barrons.com

20 feb. 2026, 20:38 UTC

Market Talk

U.S. Natural Gas Gains Ahead of Chilly Weekend -- Market Talk

Comparație

Modificare preț

Guardant Health Inc Așteptări

Obiectiv de preț

By TipRanks

28.24% sus

Prognoză pe 12 luni

Medie 132.22 USD  28.24%

Maxim 175 USD

Minim 110 USD

În baza a 20 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruGuardant Health Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

20 ratings

19

Cumpărare

1

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

38.86 / 47.41Suport & Rezistență

Termen scurt

Very Strong Bearish Evidence

Termen mediu

Bearish Evidence

Termen lung

Bullish Evidence

Sentiment

By Acuity

141 / 351 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
help-icon Live chat